Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world\u2019s most prolific diseases.
A new paper from the Heather and Tyler groups has uncovered the mechanism responsible for reduced energy in the hearts of patients with type 2 diabetes and revealed a new therapeutic strategy to reverse the energy deficit.
Researchers at the Nuffield Department of Population Health, in collaboration with other researchers, have published new findings that identify a combination of factors that put some patients at higher risk of myopathy.
DPAG researchers have collaborated on an international study that demonstrates a detailed mechanistic understanding of how the anti-malaria drug, Hydroxychloroquine, combined with antibiotics, can cause adverse cardiac side-effects in COVID-19 patients. This gives weight to US Federal advice against using this combined treatment.
DPAG's Associate Professor Mathilda Mommersteeg and Professor Paul Riley, in collaboration with Professor Robin Choudhury from the Radcliffe Department of Medicine, will perform single cell analysis of inflammation during heart regeneration with a grant from the Chan Zuckerberg Initiative.
New collaborative research from the Mommersteeg Group and MRC WIMM researchers shows that a protein called Runx1 plays a significant role in the formation of the cardiac scar that forms after the heart is injured, a scar that is known to inhibit heart regeneration. In the zebrafish, a freshwater fish known to be able to fully regenerate its heart after damage, they show that the absence of Runx1 results in enhanced regeneration. This indicates a potential new therapeutic target for heart repair.
DPAG's Dr Jakub Tomek and Professor Blanca Rodriguez's Computational Cardiovascular Science Team have developed a new computer model that recreates the electrical activity of the ventricles in a human heart. In doing so, they have uncovered and resolved theoretical inconsistencies that have been present in almost all models of the heart from the last 25 years and created a new human heart model that could enable more basic, translational and clinical research into a range of heart diseases and potentially accelerate the development of new therapies.
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage. The Riley Group study was funded by the British Heart Foundation and led by BHF CRE Intermediate Transition Research Fellow Dr Filipa Sim\u00f5es.
Up to 30,000 lives could be saved over the next decade thanks to a proposed pioneering government collaboration with pharmaceutical company Novartis to tackle heart disease \u2013 a leading cause of death in the UK.
Professor Jeremy Pearson, the BHF\u2019s longest serving Associate Medical Director, has been awarded an MBE in the Queen\u2019s New Year Honours list for services to medical research.
For many years, we have been using beta-blockers to neutralise a specific stress hormone and prevent dangerous heart rhythms following a heart attack. However, a new study led by Associate Professor Neil Herring and published in the European Heart Journal has uncovered evidence for an additional stress hormone acting as a key trigger for dangerous heart rhythms that is not currently targeted by these drugs.
![\"A](\"https://www.cardioscience.ox.ac.uk/news/paul-riley-appointed-director-of-oxford2019s-institute-of-developmental-and-regenerative-medicine/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n